Related Experiment Video

Updated: Aug 30, 2026

Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR
07:24

Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR

Published on: April 8, 2013

Levosimendan in patients with low-output heart failure: lessons from the LIDO trial

Ferenc Follath1

  • 1Department of Internal Medicine, University Hospital, Ramistrasse 100, 8091 Zurich, Switzerland. ferenc.follath@usz.ch

Italian Heart Journal : Official Journal of the Italian Federation of Cardiology
|November 26, 2003
PubMed

Insights

Levosimendan, a novel calcium sensitizer, effectively treats severe low-output heart failure by improving cardiac function and reducing mortality compared to dobutamine. This drug offers a promising new therapeutic option for patients with decompensated heart failure.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Severe low-output congestive heart failure requires effective inotropic support.
  • Current treatments like dobutamine have limitations.

Purpose of the Study:

  • To compare the efficacy and safety of levosimendan versus dobutamine in patients with severe low-output congestive heart failure.

Main Methods:

  • A double-blind clinical trial involving 203 patients.
  • 24-hour infusion of levosimendan or dobutamine.
  • Primary endpoint: achieving at least 30% increase in cardiac output and 25% decrease in pulmonary capillary wedge pressure.

Main Results:

  • Hemodynamic improvement achieved in 28% of levosimendan patients vs. 15% of dobutamine patients (p=0.022).
  • Levosimendan significantly reduced 1- and 6-month mortality (p=0.045 and p=0.029, respectively).
  • Fewer instances of myocardial ischemia and cardiac arrhythmias with levosimendan.

Conclusions:

  • Levosimendan demonstrates superior hemodynamic efficacy and improved survival in severe low-output heart failure compared to dobutamine.
  • Levosimendan offers a favorable safety profile with reduced adverse cardiac events.
  • Calcium sensitizers represent a new therapeutic avenue for decompensated heart failure.

More Related Videos

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction09:20

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction

Published on: February 13, 2021

Related Concept Videos

Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure III: Clinical Manifestations01:26

Heart Failure III: Clinical Manifestations

Heart failure (HF) manifests primarily as dyspnea, fatigue, and fluid retention, resulting in peripheral and pulmonary edema. Symptoms may vary depending on which ventricle is more affected, left or right.Left-Sided Heart FailureAlso known as left ventricular failure, this condition results from the left ventricle's inability to fill or eject sufficient blood into the systemic circulation. It leads to pulmonary congestion, which occurs when the left ventricle fails to eject blood effectively...
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...